Pedro Barata, MD, MSc


PTEN Loss in mCRPC: Caution Surrounding mTOR, PI3K, and AKT Inhibition

August 9th 2022

Panelists share caution toward use of mTOR-, PI3K-, and AKT-targeted therapies in the setting of PTEN loss in metastatic CRPC.

Therapy Overview: Sequencing Agents in Patients With Metastatic CRPC

August 9th 2022

A comprehensive review of available agents in the setting of metastatic CRPC, with discussion of optimal sequencing in later lines of therapy.

Metastatic Castration-Resistant Prostate Cancer: Optimal Imaging Strategies

August 2nd 2022

Expert oncologists define appropriate imaging strategies, conventional and novel, in patients with metastatic castration-resistant prostate cancer.

Clinical Scenario 3: A 76-Year-Old With Metastatic CRPC

August 2nd 2022

Shared insight on a clinical scenario of metastatic castration-resistant prostate cancer managed with androgen-deprivation therapy and docetaxel.

Addressing Unmet Needs in Nonmetastatic CRPC

July 26th 2022

Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.

Selecting Among Available AR Inhibitors in Nonmetastatic CPRC

July 26th 2022

A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.

Optimizing Management of nmCRPC: Patient Monitoring and Initiating Therapy

July 19th 2022

Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.

Clinical Scenario 2: A 64-Year-Old Man With nmCRPC

July 19th 2022

Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.

Improving Patient Monitoring in the Setting of Metastatic HSPC

July 12th 2022

Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.

Clinical Trial Data in Metastatic HSPC From the ASCO 2022 Annual Meeting

July 12th 2022

Expert panelists briefly share their excitement for trial data readouts in metastatic hormone-sensitive prostate cancer from the annual ASCO 2022 Annual meeting.

Establishing Eligibility for Frontline AR-Targeted Therapy in mHSPC

July 5th 2022

Continuing their discussion on frontline AR-targeted therapy in mHSPC, experts define how accessibility and patient eligibility impact treatment selection.

Factors in Selecting AR-Targeted Therapy for Patients With Metastatic HSPC

July 5th 2022

Expert perspectives on frontline AR-targeted therapy in metastatic hormone-sensitive prostate cancer, with deference to recent clinical trial data on triplet therapy.

Optimizing Management of mHSPC: Multimodality Care and Genetic Testing

June 28th 2022

A brief review of the respective roles of multidisciplinary care and genetic testing in patients diagnosed with metastatic hormone-sensitive prostate cancer.

Clinical Scenario 1: A 67-Year-Old With Metastatic HSPC

June 28th 2022

Centering discussion on a clinical scenario of metastatic hormone-sensitive prostate cancer, expert panelists consider how they might approach frontline therapy in this setting.

New Data Change Management of Frontline Metastatic Renal Cell Carcinoma

July 16th 2019

Recently, new data were presented for patients in different risk categories that significantly changed the surgical and medical management of patients with newly diagnosed metastatic renal cell carcinoma.